Date Filed | Type | Description |
08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/15/2023 |
4
| ORiordan Anne (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.158, valued at
$171.5k
|
|
08/15/2023 |
4
| O'Keefe Kenneth W (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1585, valued at
$171.5k
|
|
08/15/2023 |
4
| Winningham Rick E (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1584, valued at
$171.5k
|
|
08/15/2023 |
4
| Sohn Catherine A. (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1585, valued at
$171.5k
|
|
08/15/2023 |
4
| Smith Mark Douglas (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1579, valued at
$171.5k
|
|
08/15/2023 |
4
| RIEDEL NORBERT G (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1581, valued at
$171.5k
|
|
08/15/2023 |
4
| Mulligan Seamus (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 |
|
08/15/2023 |
4
| McSharry Heather Ann (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,344 shares
@ $138.1586, valued at
$185.7k
|
|
08/15/2023 |
4
| Henderson Mary Elizabeth (SVP, Technical Operations) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 10,763 shares
@ $0 |
|
08/15/2023 |
4
| Gray Peter (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1584, valued at
$171.5k
|
|
08/15/2023 |
4
| ENRIGHT PATRICK G (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1585, valued at
$171.5k
|
|
08/15/2023 |
4
| Cook Jennifer E. (Director) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Granted 3,075 shares
@ $0 Sold 1,241 shares
@ $138.1581, valued at
$171.5k
|
|
08/15/2023 |
4
| Carr Patricia (SVP, Chief Accounting Officer) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Sold 158 shares
@ $138.1575, valued at
$21.8k
|
|
08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
3
| Henderson Mary Elizabeth (SVP, Technical Operations) has filed a Form 3 on Jazz Pharmaceuticals plc |
08/09/2023 |
4
| Patil Neena M (EVP & Chief Legal Officer) has filed a Form 4 on Jazz Pharmaceuticals plc
Txns:
| Disposed/sold 1,390 shares
@ $131.51, valued at
$182.8k
|
|
08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/09/2023 |
8-K
| Quarterly results |
07/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/16/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
06/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/16/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|